{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:32:32Z","timestamp":1777350752474,"version":"3.51.4"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective.<\/jats:bold>\n                    Prolactinoma, as a common endocrine disorder and the most frequent type of pituitary tumor, acts primarily as a suppressor on the gonadal functions. It is generally successfully treated with dopamine agonists; however, treatment resistance still remains in an unneglectable ratio. In this study, we aimed to identify factors, which may play a role in the treatment response.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    Seventy-six patients with prolactinoma, who have been routinely followed between 2018 and 2022 in Istanbul Research and Educational Hospital Endocrinology Outpatient Clinic, were included into the study. Initial prolactin level, adenoma size, baseline weight, body mass index (BMI), glucose, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels were obtained from the patient\u2019s medical records. The patients were divided into two groups: treatment respondent and non-respondent (refractory) ones, according to treatment response in the duration as suggested by the guidelines. The treatment respondent and non-respondent groups were compared according to the initial and the 3rd month prolactin levels, adenoma size, weight, BMI, and metabolic values.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    The initial tumor diameter was 15.27\u00b110.62 mm in the refractory and 7.42\u00b14.42 mm in the treatment respondent groups (p=0.01). The refractory group had higher prolactin baseline level 269.96\u00b1275.78 \u00b5g\/l vs. 124.55\u00b167.35 \u00b5g\/l of the respondent group (p=0.01). The refractory group had higher the 3rd month prolactin level 50.97\u00b152.55 \u00b5g\/l vs. 29.70\u00b127.31 \u00b5g\/l of the respondent group (p=0.04). The refractory group had higher frequency of cystic\/hemorrhagic adenoma (47.6%, n=11\/21) (p=0.01), baseline pituitary failure (33.3%, n=7\/21) (p=0.01), and baseline cavernous sinus invasion (25.8, n=5\/21) (p=0.01). The treatment respondent group had lower initial body weight (69.54\u00b117.51 kg vs. 83.29\u00b116.21 kg) (p&lt;0.01), and lower BMI (25.98\u00b15.47 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    vs. 27.69\u00b16.42 kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) (p=0.02).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.<\/jats:bold>\n                    In this study, initial tumor size, male gender, weight, BMI, the 3rd month prolactin level, initial pituitary deficiency, and cystic\/hemorrhagic component in pituitary imaging in patients with prolactinoma were associated with a lower treatment response.\n                  <\/jats:p>","DOI":"10.2478\/enr-2022-0030","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T03:21:12Z","timestamp":1666236072000},"page":"279-283","source":"Crossref","is-referenced-by-count":6,"title":["Prolactinoma - which patients react favorably to cabergoline medication?"],"prefix":"10.2478","volume":"56","author":[{"given":"Savas","family":"Karatas","sequence":"first","affiliation":[{"name":"Endocrinology and Metabolism Department , Istanbul Research and Education Hospital , Istanbul , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalcin","family":"Hacioglu","sequence":"additional","affiliation":[{"name":"Family Medicine Department , Istanbul Research and Education Hospital , Istanbul , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taskin","family":"Rakicioglu","sequence":"additional","affiliation":[{"name":"Radiology Department , Istanbul Research and Education Hospital , Istanbul , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2026042722161770074_j_enr-2022-0030_ref_001","doi-asserted-by":"crossref","unstructured":"Abbara A, Clarke SA, Nesbitt A, Ali S, Comninos AN, Hatfield E, Martin NM, Sam AH, Meeran K, Dhillo WS. Interpretation of serum gonadotropin levels in hyperprolactinaemia. Neuroendocrinology 107, 2, 105\u2013113, 2018.10.1159\/00048926429660734","DOI":"10.1159\/000489264"},{"key":"2026042722161770074_j_enr-2022-0030_ref_002","doi-asserted-by":"crossref","unstructured":"Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am 4, 89\u201397, 2015.10.1016\/j.ecl.2014.10.00725732645","DOI":"10.1016\/j.ecl.2014.10.007"},{"key":"2026042722161770074_j_enr-2022-0030_ref_003","doi-asserted-by":"crossref","unstructured":"Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol 846, 1\u201335, 2015.10.1007\/978-3-319-12114-7_125472532","DOI":"10.1007\/978-3-319-12114-7_1"},{"key":"2026042722161770074_j_enr-2022-0030_ref_004","doi-asserted-by":"crossref","unstructured":"Bernard V, Young J, Binart N. Prolactin \u2013 a pleiotropic factor in health and disease. Nat Rev Endocrinol 15, 356\u2013365, 2019.10.1038\/s41574-019-0194-630899100","DOI":"10.1038\/s41574-019-0194-6"},{"key":"2026042722161770074_j_enr-2022-0030_ref_005","doi-asserted-by":"crossref","unstructured":"Bima C, Chiloiro S, Giampietro A, Gessi M, Mattogno PP, Lauretti L, Anile C, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. Galectin-3 and estrogen receptor alpha as prognostic markers in prolactinoma: preliminary results from a pilot study. Front Endocrinol 12, 684055, 2021.10.3389\/fendo.2021.684055831224534322092","DOI":"10.3389\/fendo.2021.684055"},{"key":"2026042722161770074_j_enr-2022-0030_ref_006","doi-asserted-by":"crossref","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65, 265\u2013273, 2006.10.1111\/j.1365-2265.2006.02562.x16886971","DOI":"10.1111\/j.1365-2265.2006.02562.x"},{"key":"2026042722161770074_j_enr-2022-0030_ref_007","doi-asserted-by":"crossref","unstructured":"Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33, 101290, 2019.10.1016\/j.beem.2019.10129031326373","DOI":"10.1016\/j.beem.2019.101290"},{"key":"2026042722161770074_j_enr-2022-0030_ref_008","doi-asserted-by":"crossref","unstructured":"Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11, 787\u2013800, 2002.10.1517\/13543784.11.6.78712036422","DOI":"10.1517\/13543784.11.6.787"},{"key":"2026042722161770074_j_enr-2022-0030_ref_009","doi-asserted-by":"crossref","unstructured":"Colao A, di Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148, 325\u2013331, 2003.10.1530\/eje.0.148032512611613","DOI":"10.1530\/eje.0.1480325"},{"key":"2026042722161770074_j_enr-2022-0030_ref_010","doi-asserted-by":"crossref","unstructured":"Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82, 2102\u20132107, 1997.10.1210\/jc.82.7.2102","DOI":"10.1210\/jc.82.7.2102"},{"key":"2026042722161770074_j_enr-2022-0030_ref_011","doi-asserted-by":"crossref","unstructured":"Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16, 545\u2013553, 2013.10.1007\/s11102-012-0454-023239049","DOI":"10.1007\/s11102-012-0454-0"},{"key":"2026042722161770074_j_enr-2022-0030_ref_012","doi-asserted-by":"crossref","unstructured":"Hu J, Zheng X, Zhang W, Yang H. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18, 745\u2013751, 2015.10.1007\/s11102-014-0617-225500765","DOI":"10.1007\/s11102-014-0617-2"},{"key":"2026042722161770074_j_enr-2022-0030_ref_013","doi-asserted-by":"crossref","unstructured":"Kars M, Souverein PC, Herings RM, Romijn JA, Vandenbroucke JP, de Boer A, Dekkers OM. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab 94, 2729\u20132734, 2009.10.1210\/jc.2009-017719491225","DOI":"10.1210\/jc.2009-0177"},{"key":"2026042722161770074_j_enr-2022-0030_ref_014","unstructured":"Lu C, Liu Y, Lu Z, Huan C. Ki-67 and clinical correlations in patients with resistant prolactinomas. Ann Clin Lab Sci 50, 199\u2013204, 2020."},{"key":"2026042722161770074_j_enr-2022-0030_ref_015","doi-asserted-by":"crossref","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 273\u2013288, 2011.10.1210\/jc.2010-169221296991","DOI":"10.1210\/jc.2010-1692"},{"key":"2026042722161770074_j_enr-2022-0030_ref_016","doi-asserted-by":"crossref","unstructured":"Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51, 205\u2013210, 2016.10.1007\/s12020-015-0727-226336835","DOI":"10.1007\/s12020-015-0727-2"},{"key":"2026042722161770074_j_enr-2022-0030_ref_017","doi-asserted-by":"crossref","unstructured":"Posawetz AS, Trummer C, Pandis M, Aberer F, Pieber TR, Obermayer-Pietsch B, Pilz S, Theiler-Schwetz V. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study. BMC Endocr Disord 26, 21, 81, 2021.","DOI":"10.1186\/s12902-021-00733-6"},{"key":"2026042722161770074_j_enr-2022-0030_ref_018","doi-asserted-by":"crossref","unstructured":"Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, Rodari G, Filopanti M, Ferrante E, Spada A, Mantovani G. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas. J Endocrinol Invest 39, 1377\u20131382, 2016.10.1007\/s40618-016-0483-z27245604","DOI":"10.1007\/s40618-016-0483-z"},{"key":"2026042722161770074_j_enr-2022-0030_ref_019","doi-asserted-by":"crossref","unstructured":"Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ER Jr. Current indications for the surgical treatment of prolactinomas. J Clin Neurosci 22, 1785\u20131791, 2015.10.1016\/j.jocn.2015.06.00126277642","DOI":"10.1016\/j.jocn.2015.06.001"},{"key":"2026042722161770074_j_enr-2022-0030_ref_020","doi-asserted-by":"crossref","unstructured":"Teixeira M, Souteiro P, Carvalho D. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal. Pituitary 20, 464\u201370, 2017.10.1007\/s11102-017-0806-x28523537","DOI":"10.1007\/s11102-017-0806-x"}],"container-title":["Endocrine Regulations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/enr-2022-0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T03:36:18Z","timestamp":1777347378000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/enr-2022-0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2022,10,1]]}},"alternative-id":["10.2478\/enr-2022-0030"],"URL":"https:\/\/doi.org\/10.2478\/enr-2022-0030","relation":{},"ISSN":["1336-0329"],"issn-type":[{"value":"1336-0329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}